![conference banner](/images/conference-banner.jpeg)
摘要
在各种不同的药物传递装置中,纳米脂质体是癌症治疗中一个新兴的制剂。在这里,我们已经开发枸橼酸他莫昔芬与磷酸乙醇胺(PE)结合(TC)采用薄膜水化的方法负载纳米脂质体。进行了如药物 - 赋形剂相互作用、表面形态、能量色散x射线分析,电动电势,体外药物释放,细胞吸收,体外细胞毒性试验和体内药代动力学特性的各种物理化学和生物制药表征研究。TC-装载纳米脂质体(TNL1)和PE缀合的TC-装载纳米脂质体(TNL-PE)分别显示3.23±0.26%和3.07±0.05%药物负载值。纳米脂质体的平均直径(Z平均)在100纳米内,负电位电势,TNL1和TNL-PE 30小时药物释放的累积百分比分别为75.77±12.21%和61.04±10.53%。两种纳米脂质在MCF-7中乳腺癌细胞中显现主要摄取。TNL1和TNL-PE降低细胞活力分别从95.95±0.37至12.22±0.64%和从96.51±0.24至13.49±0.08%。体内药代动力学研究表明,TNL-PE的AUC 0-∞,AUMC0-∞,MRT,和T1 / 2值同游离药物相比分别增加(22%,100%,2.66倍和60%)。TNL-PE监管比游离药物减少肾清除率值(大约38%)。TNL1和TNL-PE以持续的方式释放药物。此外,TNL-PE可以作为乳腺癌细胞的有效靶向当其与特定的抗体PE——一个链接器分子标记时。
关键词: MCF-7乳腺癌细胞系、磷酸乙醇胺共轭纳米脂质体、持续方式、他莫昔芬柠檬酸盐
Current Cancer Drug Targets
Title:Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer
Volume: 16 Issue: 4
Author(s): Niladri Shekhar Dey, Biswajit Mukherjee, Ruma Maji, Bhabani Sankar Satapathy
Affiliation:
关键词: MCF-7乳腺癌细胞系、磷酸乙醇胺共轭纳米脂质体、持续方式、他莫昔芬柠檬酸盐
摘要: Among the various drug delivery devices, nanoliposome is an emerging formulation in the treatment of cancer. Here we have developed tamoxifen citrate (TC) loaded nanoliposome conjugated with phosphoethanolamine (PE) by thin film hydration method. Various physicochemical and biopharmaceutical characterization studies such as drug-excipients interaction, surface morphology, energy dispersive X-ray analysis, zeta potential, in vitro drug release, cellular uptake, in vitro cytotoxicity assay and in vivo pharmacokinetic profiles were conducted. TC-loaded nanoliposome (TNL1) and PE-conjugated TC-loaded nanoliposome (TNL-PE) showed 3.23±0.26% and 3.07±0.05% drug loading values, respectively. Average diameters (z-average) of the nanoliposomes were within 100 nm, with negative zeta potentials and cumulative percentages of drug release were 75.77±12.21% and 61.04±10.53% at 30 h for TNL1 and TNL-PE respectively. Predominant uptake of both the types of nanoliposomes was visualized in MCF-7 breast cancer cells. TNL1 and TNL-PE decreased the cell viability from 95.95±0.37 to 12.22±0.64% and from 96.51±0.24 to 13.49±0.08% respectively. In vivo pharmacokinetic study showed that AUC 0-∞, AUMC0-∞, MRT, and t1/2 value of TNL-PE increased (22%, 100%, 2.66 fold and 60% respectively) as compared to the free drug. Administration of TNL-PE decreased the renal clearance value (about 38%) as compared to the free drug. TNL1 and TNL-PE released the drug in a sustained manner. Further, TNL-PE may be used for active targeting for breast cancer cells when it is tagged with specific antibodies to PE, a linker molecule.
Export Options
About this article
Cite this article as:
Niladri Shekhar Dey, Biswajit Mukherjee, Ruma Maji, Bhabani Sankar Satapathy , Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer, Current Cancer Drug Targets 2016; 16 (4) . https://dx.doi.org/10.2174/1568009616666151106120606
DOI https://dx.doi.org/10.2174/1568009616666151106120606 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutically-induced Autoantibodies in Patients Treated with Recombinant Hematopoietic Growth Factors: A Brief Summary
Current Pharmaceutical Design Nanoparticles, Promising Carriers in Drug Targeting: A Review
Current Drug Therapy Phenotypic Alteration of Bone Marrow HSC and Microenvironmental Association in Experimentally Induced Leukemia
Current Stem Cell Research & Therapy Gambogic Acid is a Novel Anti-cancer Agent that Inhibits Cell Proliferation, Angiogenesis and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Validation and Development of N-glycan as Biomarker in Cancer Diagnosis
Current Pharmacogenomics and Personalized Medicine The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry A Facile Total Synthesis of Kilogram-Scale Production of SKLB1039: A Novel and Selective Hexahydroisoquinolin-Containing EZH2 Inhibitor
Current Organic Synthesis Therapeutic Potential, Synthesis, Patent Evaluation and SAR Studies of Thieno[3,2-d]pyrimidine Derivatives: Recent Updates
Current Drug Targets Simple C-2-Substituted Quinolines and their Anticancer Activity
Letters in Drug Design & Discovery Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine Antitumor Effects of Curcumin on Cervical Cancer with the Focus on Molecular Mechanisms: An Exegesis
Current Pharmaceutical Design Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets Bioactives in Disease Prevention and Health Promotion: Exploiting Combinatorial Effects
Current Bioactive Compounds Isolation and Characterization of a Lectin from Japanese Mottled Beans
Protein & Peptide Letters Apoptosis Signaling Pathways in Anticancer Therapy
Current Cancer Therapy Reviews Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Could Resveratrol be a Useful Drug for the Treatment of Malignant Hemopathies?
Recent Patents on Anti-Cancer Drug Discovery Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Estrone (E1) Based Esters as Potential Inhibitors of Type 3 17β- hydroxysteroid Dehydrogenase (17β-HSD3) in the Treatment of Hormone-Dependent Prostate Cancer
Letters in Drug Design & Discovery